Prostate carcinoma: Defining therapeutic objectives and improving overall outcomes

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 758-771

  Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clinical states; Hormone therapy; Metastases; Prostate carcinoma; Tumor biology

Indexed keywords

ANTIANDROGEN; CYCLIN D1; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KI 67 ANTIGEN; LEXIDRONAM SAMARIUM SM 153; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; PROTEIN P53; STRONTIUM 89;

ALGORITHM; BONE METASTASIS; CANCER HORMONE THERAPY; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; HORMONAL REGULATION; HUMAN; LUTEINIZING HORMONE RELEASE; OUTCOMES RESEARCH; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT PLANNING;

EID: 0037303769     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11151     Document Type: Conference Paper

References (100)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Yao S-L, Lu-Yao G. Changing patterns in competing causes of death among men with prostate cancer [abstract 722]. Proc Am Soc Clin Oncol. 2002;;21:181a.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression to metastases an death from prostate cancer in men with PSA recurrence following radical prostatectomy. JAMA. 1999;281:1591-1597.
4. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst. 1996;88:1623-1634.
5. Scher HI, Heller G. Clinical states in prostate cancer: towards a dynamic model of disease progression. Urology. 2000;55:323-327.
6. Moul JW. Rising PSA after local therapy failure: Immediate vs deferred treatment. Oncology. 1999;13:985-993.
7. Nasr R, Goldenberg SL. Rising prostate specific antigen after radical prostatectomy: a case based review. Can J Urol. 2001;8:1306-1313.
8. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562-1568.
9. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030-1039.
10. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Cancer. 1997;79:528-537.
11. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychological distress in men with prostate cancer: a pilot study. Cancer. 1998;82: 1904-1908.
12. Scher HI, Isaacs JT, Fuks Z, Walsh PC. Prostate cancer. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. Clinical oncology. New York: Churchill Livingstone, 1995: 1439-1472.
13. Taplin ME, Ho SM. Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab. 2001;86:3467-3477.
14. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
15. Huggins C, Stevens RE Jr., Hodges CV. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-223.
16. Mittelman A, Shukla SK, Welvaart K, Murphy GP. Oral estramustine phosphate (NSC-89199) in the treatment of advanced (stage D) carcinoma of the prostate. Cancer Chemother Rep. 1975;59:219-223.
17. Geller J. Overview of enzyme inhibitors and anti-androgens in prostatic cancer. J Androl. 1991;12:364-371.
18. McLeod DG, Kolvenbag GJCM. Defining the role of antiandrogens in the treatment of prostate cancer. Urology. 1996; 47:85-89.
19. Kaisary A, Tyrrell CI, Peeling WB, Griffiths K. Comparison of LHRH analogues (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1989;67: 502-508.
20. Group. TLS. Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med. 1984;311:1281-1286.
21. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology. 1989;33(Suppl):57-62.
22. Waxman J, Man A, Hendry WF, et al. Important of early tumour exacerbation in patients treated with long acting analogues of gonadotropin releasing hormone for advanced prostatic cancer. Br Med J. 1985;291:1387-1388.
23. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4:579-594.
24. Group PCTC. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5711 patients. Lancet. 1995;346:265-269.
25. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a metaanalysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis. 1999;2:4-8.
26. Caubet J, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997;49:71-78.
27. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advance prostate cancer. Cochrane Database Syst Rev. 2000;(2) CD001526.
28. Crawford ED, Eisenberger MA, McLoed DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-424.
29. Kolvenbag GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex®) in the treatment of prostate cancer: history of clinical development. Prostate. 1998;34:61-72.
30. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of "Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447-456.
31. Trachtenberg J, Gittleman M, Steidle C, et al. A Phase 3, multicenter, open label, randomized study of abarelix versus leuprlide plus daily anti-androgen in men with prostate cancer. J Urol. 2002;167:1670-1674.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
33. Smith PH, Bono A, Calais da Silva F, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer. 1990;66:1009-1016.
34. Fair WR, Aprikian AG, Cohen D, Sogani PC, Reuter V. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med. 1993;16:516-522.
35. Moul JW. Neoadjuvant hormonal therapy for clinically localized prostate cancer. Urol Ann. 1996;1046:47-56.
36. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. j Natl Cancer Inst Monogr. 1988;7:165-170.
37. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997:295-300.
38. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
39. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235-246.
40. See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer Program. Demography. 2001;6:43-47.
41. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 2002;168:429-435 [Erratum: J Urol. 2002;168;4(Pt 1):150; 2002;168(6):2558].
42. Wirth M, See D, McLeod D, Iversen P, Persson BE, Carroll K. Bicalutamide (Casodex) 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer [abstract 705]. Proc Am Soc Clin Oncol. 2001;20:177a.
43. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992;339:1-15.
44. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.
45. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide (Casodex) compared with flutamide (Eulexin) in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a doubleblind, randomized, multicenter trial. Urology. 1997;50:330-336.
46. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes: pathophysiology and clinical significance. Urol Clin North Am. 1997;24:421-433.
47. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997;15:382-388.
48. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
49. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;18:2506-2513.
50. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53.
51. Pienta KJ, Fisher EI, Eisenberger MA, et al. A Phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group Trial (SWOG 9407). Prostate. 2001;46:257-261.
52. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001;19:2509-2516.
53. Petrylak DP, MacArthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
54. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP. Transplantation of human prostatic carcinoma into nude mice in matrigel. Cancer Res. 1991;51:3814-3817.
55. Pretlow TG, Wolman SR, Micale MA, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst. 1993;85:394-398.
56. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869-1876.
57. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol. 1988;138:1460-1465.
58. Scher HI, Chung LWK. Bone metastases: biology and therapy. Semin Oncol. 1994;21:630-656.
59. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res. 1998;4:1765-1772.
60. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metast Rev. 2001;20:333-349.
61. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol. 2001;11:483-488.
62. Akimoto S, Okumura A, Fuse H. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocrine J. 1998;45:183-189.
63. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulinlike growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992;75:1046-1053.
64. Sugihara A, Maeda O, Tsuji M, et al. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Oncol Rep. 1998;5:1389-1394.
65. Bryden AA, Hoyland JA, Freemont AJ, Clarke NW, George NJ. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer. 2002;86:322-325.
66. Sabbatini P, Larson S, Kremer AB, et al. The prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999; 17:948-957.
67. Slovin SF, Scher HI. Detectable tumor cells in the blood and bone marrow: smoke or fire? Cancer. 1998;83:394-398.
68. Weckermann D, Muller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol. 1999;17:3438-3443.
69. Wood DR, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol, 1997;15:3451-3457.
70. Wood DR, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer. 1994;74:2533-2540.
71. Sabbatini P, Yeung H, Imbriaco M, et al. The correlation of serial bone scintigraphy and PSA determinations in patients (Pts) with androgen independent prostate cancer. Proc Am Soc Clin Oncol. 1996;15:254.
72. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cycle D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6:1891-1895.
73. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913-918.
74. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-613.
75. Fazzari M, Heller G, Scher HI. The Phase II/III transition: towards the proof of efficacy in cancer clinical trials. Control Clin Trials. 2000;21:360-368.
76. Carducci MA, Vogelzang NJ, Daliani D, et al. Controlled Phase II dose-ranging evaluation of an endothelin-A receptor antagonist for men with hormone refractory prostate cancer (HRPCa) and disease-related pain [abstract 1314]. Proc Am Soc Clin Oncol. 2000;19:334a.
77. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate cancer. Cancer. 2000;89:1329-1348.
78. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
79. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280-285.
80. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
81. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940-6944.
82. Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002;94:980-986.
83. Bookstein R, MacGrogan D, Hilsenbck SG, Sharkey F, Allfred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993;53:3369-3373.
84. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res. 1998;2:389-398.
85. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol. 1993;7:1541-1550.
86. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen-independence. Clin Cancer Res. 1996;2:277-285.
87. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res. 2001;7:1273-1281.
88. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Casodex® (200 mg) for advanced prostate cancer: the natural vs. treated history of disease. J Clin Oncol. 1997;15:2928-2938.
89. Chang SS, Reuter VE, Heston DWD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59: 3192-3198.
90. Agus DB, Cordon-Cardo C, Fox W, et al. Alterations of cell cycle regulators in prostate cancer: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869-1876.
91. Kelly WK, Richon VM, Troso-Sandoval T, et al. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: biologic activity without toxicity [abstract 344]. Proc Am Soc Clin Oncol. 2001;20:87a.
92. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res. 1996;2: 379-387.
93. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res. 1999; 5:2891-2898.
94. DiPaola S, Rafi M, Toppmeyer D, et al. bcl-2 modulation with 13-cis retinoic acid, alpha interferon and paclitaxel in vitro and in patients with prostate cancer and advanced malignancy [abstract 1242]. Proc Am Soc Clin Oncol. 1999; 18:323a.
95. Solit D, Zheng F, Munster P, et al. 17-allyl-amino-geldanamyicn (17-AAG) induces the degradation of AR and HER2 in prostate cancer xenograft tumors and inhibits their growth [abstract 1954]. Proc Am Assoc Cancer Res. 2001;42: 363.
96. Porter A, Order S, Caplan R, Gallagher M, McGowan D, Lustig R. Report of a multiinstitutional Phase I/II study to evaluate the use of strontium therapy in metastatic prostate cancer. Radiation Therapy Oncology Group. Proc Am Soc Clin Oncol. 1994;13:1540.
97. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33-40.
98. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
99. Fred S, Gleason D, Murray R, Venner P, Tchekmediyian S, Chin J, et al. Zoledronic acid significantly reduces fractures in patients with hormone-refractory prostate cancer metastatic to bone [abstract 703]. J Urol. 2002;167:175.
100. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet. 2001;357:336-341.